The influence of combined treatment of simvastatin and amitriptyline on some biochemical parameters in rat serum

Authors

  • Mariola Herbet Department of Toxicology, Medical University of Lublin, Poland Author
  • Monika Gawrońska-Grzywacz Department of Toxicology, Medical University of Lublin, Poland Author
  • Ewa Jagiełło-Wójtowicz Department of Toxicology, Medical University of Lublin, Poland Author

Keywords:

simvastatin, amitriptyline, biochemical parameters

Abstract

The aim of this study was to estimate a 14-day simultaneous usage of simvastatin and amitriptyline on the some biochemical parameters indicating liver and kidney functions in rats. The estimation of the activity of AST, ALT and the concentration of total protein, creatinine, urea, α-fetoprotein and β2-microglobuline was conducted. The results show that after 14 days of combined application with simvastatin and amitriptyline some changes were observed in the biochemical parameters examined. It seems that the combined treatment with simvastatin and amitriptyline is possible on condition of a regular control of parameters indicating liver and kidney functions.

References

1. Bottorf M.B.: Statin safety and drug interactions: clinical implications. Am. J. Cardiol., 97, 27C , 2006.

2. Chalasani N., Hisham A., Kesterson J., Murray M. D., Hall S. D.: Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology, 126, 1287, 2004.

3. Chalasani N.: Statins and hepatotoxicity: focus on patients with fatty liver. Hepatology, 41, 690, 2005.

4. Charles E.C., Olson K.L., Sandhoff B.G., McClure D.L., Merenich J.A.: Evaluation of cases of severe statin-related transaminitis within a large health maintenance organization. Am J Med, 118, 618, 2005.

5. Cohen D.E., Anania F.A., Chalasani N.: An Assessment of Statin Safety by Hepatologists. Am. J. Cardiol., 97, S77, 2006.

6. Gibson K., Rindone J.P.: Experience with statin use in patients with chronic hepatitis C infection. Am. J. Cardiol., 96, 1278, 2005.

7. Herman R.J.: Drug interactins and the statins. CMAJ, 161 9100, 1281, 1999.

8. Hyogo H., Tazuma S., Arihiro K., et al.: Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia. Metabolizm, 57, 1711, 2008.

9. Jacobson T.A.: Statin Safety: Lessons from New Drug Applications for Marketed Statins. Am J Cardiol, 97, S44, 2006.

10. Karnik N.S., Maldonado J.R.: Antidepressant and statin interactions: a review and case report of simvastatin and nefazodone-induced rhabdomyolysis and transaminitis. Psychosomatics, 46, 565, 2005.

11. Kasiske B.L., Wanner C., O’Neill W.C.: An Assessment of Statin Safety by Nephrologists. Am. J. Cardiol., 97, S82, 2006.

12. Kassimatis T. I., Konstantinopoulos P.A.: The role of statins in chronic kidney disease (CKD): Friend or foe?. Pharmacol. Ther., 312, 2009.

13. Kim J. S., Schmid-Burgk W., Claus D., Kornhuber H.H.: Effevts of Amitriptyline on Serum Glutamate and Free Tryptophan in Rats. Arch. Psychiatr. Nervenkr., 232, 391, 1982.

14. Maddrey W.C.: Drug-induced liver disease: 2006. The risk profile of statins. American Association for the Study of the Liver disease. Annual Meeting, Boston 2006.

15. Mitchell D.B., Acosta D.: Evaluation of the cytotoxicity of tricyclic antidepressants in primary cultutes of rat hepatocytes. J. Toxicol. Environ. Health, 7, 83, 1981.

16. Paoletti R., Corsini A., Bellosta S.: Pharmacological interaction of statins. Atherosclerosis, (Suppl. 3), 35, 2002.

17. Patassini S., Giampa C., Martorana A., Bernardi G., Cusco FR.: Effect of simvastatin on neurorotection and modulation of Bcl-2 and BAX in the rat quinolinic acid model of Huntington´s disease, Neurosci. Lett., 19, 166, 2008.

18. Ray K.K., Cannon C.: The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes. J. Am. Coll. Cardiol., 46, 1425, 2005.

19. Segarra-Newnham M., Parra D., Martin-Cooper E.M.: Effectiveness and hepatotoxicity of statins in men seropositive for hepatitis C virus. Pharmacoteraphy, 27, 845, 2007.

20. Skrabal M.Z., Stading J.A., Monaghan M.S.: Rhabdomyolysis associated with simvastatin-nefazodone therapy. South Med. J., 96, 1034, 2003.

21. Smith C.C., Bernstein L. I., Davis R.B. et al.: Screening for Statin-Related Toxicity: The Yield of Transaminase and Creatine Kinase Measurements in a Primary Care Setting. Arch. Intern. Med., 163, 688, 2003.

22. Talbert R.L.: Safety issues with statin therapy. J. Am. Pharm. Assoc., 46, 479, 2006.

23. Tousoulis D., Charakida M., Stefanadi E. et al.: Statins in heart failure. Beyond the lipid lowering effect. Intern. J. Cardiol., 115, 144, 2007.

24. Wang C.Y., Liu P.Y., Liao J.K.: Pleiotropic effects of statin therapy: molecular mechanisms and clinical results, Trends Mol. Med., 14, 37, 2008.

25. Wen B., M Li., Z. Mingshe.: Bioactivation of the tricyclic antidepressant amitriptyline and its metabolite nortriptyline to arene oxide intermediates in human liver microsomes and recombinant P450s. Chemico-Biological Interactions, 173, 59, 2008.

26. Wille S.M., Cooreman S.G., Neels H.M., Lambert W.E.: Relevant issues in the monitoring and the toxicology of antidepressants. Crit. Rev. Clin. Lab. Sci., 45, 25, 2008.

Downloads

Published

2010-12-30

Issue

Vol. 23 No. 4 (2010): Annales UMCS, Pharmacia, Sectio DDD, Volume XXIII

Section

Artykuły

License

Copyright (c) 2010 Authors

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 Unported License.